Octet® RH96 BLI System
Unrivaled performance with 2 minutes to quantitate 96 samples or 15 minutes to run 384 binding kinetics.
Receive your quote directly from the manufacturer.
The Octet® RH96 is the flagship of the instrument range. The system utilises BLI enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed and throughput.
The RH96 measures up to 96 samples simultaneously allowing both unlimited characterization capacity for various applications and custom assay tailoring to maximize analytical throughput or sensitivity and preventing bottlenecks.
Rapid whole-plate detection is accomplished using the 96 biosensor mode, providing either quantitation data for 96 samples in as little as 2 minutes or full plate kinetic screening in minutes instead of hours. The system also comes integration ready for automation, extending the unattended runtime and allowing you more time away from the bench.
Key applications that leverage the unique strengths of the Octet®RH96 system include epitope binning experiments, off-rate ranking, and titer concentration.
Key Benefits:
- Unmatched throughput – Up to 96-well simultaneous sampling in 384-well and 96-well format
- Sensitivity – Detection of low molecular weight molecules (≥ 150 Da)
- Flexibility – Two plate locations maximize throughput and improve workflow
- Unattended operation – Automation friendliness allows multiple-plate assays in one run
- User friendliness – Advanced software tools for epitope binning analysis
High-throughput screening automation and BLI technology implementation at Sanofi for engineering next-generation multi-specific antibody therapeutics
Wednesday, September 17, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Join Anja Wille as she explores how Sanofi has transformed antibody therapeutic development through advanced automation and screening technologies. Discover an end-to-end automated platform to engineer next-generation multi-specific antibody therapeutics at unprecedented scale.
She will cover the shift from traditional workflows to high-throughput platforms handling 10,000+ variants, and how the integration of multiple robotic platforms streamlines DNA handling, protein expression, and analysis.
The webinar will highlight how this integrated approach has successfully executed over 30 campaigns, significantly increasing the probability of success while generating valuable data for machine learning and AI applications.
Plus, you will learn about the use of biolayer interferometry (BLI) technology for rapid quantitation and off-rate screening and see real-world success stories, including Fab affinity maturation campaigns.
Key learning objectives:
- Understand how an integrated automated platform transforms traditional antibody development into a high-throughput process capable of handling 10,000+ variants simultaneously
- Learn about the implementation and benefits of BLI technology for rapid quantitation and off-rate screening, including practical insights from real campaign data
- Discover how automation across the entire value chain (from DNA handling to protein analysis) increases the probability of success and generates valuable data for AI applications
Who should attend?
- Biopharmaceutical R&D scientists - Particularly those working in antibody engineering, protein science, and therapeutic development
- Laboratory automation specialists - Professionals interested in high-throughput screening technologies and workflow optimization
- Assay development scientists - Those working with or interested in BLI technology applications for quantitation and binding kinetics
- Bioprocess engineers - Professionals involved in scaling antibody production and quality assessment
- Research directors and managers - Decision-makers evaluating technologies to enhance R&D productivity and efficiency
- Academic researchers - Scientists in immunology, protein engineering, and biotherapeutics development seeking insights into industrial-scale approaches
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Tools to streamline cell line development for biotherapeutics
Commercialization of a biologic is a lengthy and expensive process. Successful cell line development (CLD) is heavily dependent upon balancing time and resources with acquiring high-quality data for informed decisions. Each stage of the CLD workflow has challenges and there is a real need for advanced strategies and intelligent use of innovative solutions.
The CellCelector, iQue®, Octet®, and Ambr® 15 CC platforms are perfectly designed to seamlessly work together to streamline the early CLD workflow, enabling data-driven decisions and reducing risk during later stages of biologic development. In this webinar, Dr. Fern Slingsby, Ambr Product Specialist at Sartorius and Dr. Daryl Cole, Applications Scientist at Sartorius, will explain how integration of these platforms can be achieved, and where they best fit into the cell line development workflow.
Key learning objectives
- Learn about the early CLD workflow and the bottlenecks associated with the various stages
- Discover instruments which are suited to high-throughput demands and where they fit into the CLD workflow
- Establish a strategy for a simplified approach to cell line development
Who should attend?
- Analytical scientists and researchers involved in early drug discovery and cell line development
- Bioprocessing engineers and scientists
- Process development engineers and scientists
- Lab managers
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Accelerate assay development and reduce cycle times for AAV quantification in complex biological samples
Assessing AAV vector quality in gene therapy manufacturing is crucial, but the current gold standard, serotype-specific ELISA, has its drawbacks — time-consuming and prone to matrix effects. In this webinar, Dr. Yoann Saucereau from ExcellGene reveals how a label-free approach not only cut down on complexities in biological matrices but also enabled a quick, routine method. Now, ExcellGene effortlessly analyzes up to 96 samples in under 30 minutes for efficient AAV platform development.
Key learning objectives
- Explore how suitable QC workflows are established in AAV development and manufacturing
- Discover the critical role of assay design and development to determine correct binding kinetics, affinity values or analyte concentrations
- Consider the optimization and evaluation of an AAV titer assay in comparison to Octet® AAVX Biosensors
Who should attend?
- Lab researchers
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Accelerating discovery with Green Button Go scheduling
Dustin Whitson, an applications consulting scientist at Biosero, shares how the company is working to achieve its mission to enhance scientific discovery through software and laboratory automation.
Whitson introduces Biosero's recent partnership with Sartorius, integrating the Octet® BLI platform with Biosero's automation and software capabilities, with the goal of putting the power of automation in the hands of more scientists to help accelerate drug discovery.
This video was filmed at SLAS2025.
High-throughput binding and kinetics analysis unveiled
Dr. Nilshad Salim, Global Product Manager at Sartorius, introduces an exciting new integration of the Octet® BLI platform with Biosero’s automation capabilities and Green Button Go software.
Learn how this integration will enhance the measurement of binding strength, kinetics, and protein concentration, with the increased automation enabling labs to efficiently analyze thousands of samples, significantly improving operational efficiency.
This video was filmed at SLAS2025.
